Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832188 | 0.81 | GPR35 (0.58) | TSHRALDH1A1CA12GPR35CYP3A4 | |
| SCHEMBL1589671 | 0.81 | BACE1 (0.50) | TSHRALDH1A1CA12SNCAGPR35 | |
| SCHEMBL29901077 | 0.81 | BACE1 (0.50) | TSHRALDH1A1CA12SNCAGPR35 | |
| SCHEMBL31672310 | 0.79 | TSHR (0.60) | TSHRALDH1A1GPR35CYP3A4 | |
| SCHEMBL16951743 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1CA12SNCAGPR35 | |
| SCHEMBL2768561 | 0.79 | TDP1 (0.58) | TSHRALDH1A1CA12SNCAGPR35 | |
| SCHEMBL2766494 | 0.79 | TDP1 (0.58) | TSHRALDH1A1CA12SNCAGPR35 | |
| SCHEMBL68181 | 0.79 | TSHR (0.58) | TSHRALDH1A1CYP3A4CYP1A2MAPK1 | |
| SCHEMBL68019 | 0.79 | TSHR (0.60) | TSHRALDH1A1GPR35CYP3A4 | |
| SCHEMBL31164660 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1CA12SNCAGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112271228-A | Luminescent solar concentrator comprising disubstituted benzoheterodiazole compounds | 艾尼股份公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10312395-B2 | Luminescent solar concentrator comprising disubstituted benzoheterodiazole compounds | ENI S.P.A. (IT) | 2019-06-04 | — | — | US | disclosed |
| EP-3198658-B1 | LUMINESCENT SOLAR CONCENTRATOR COMPRISING DISUBSTITUTED BENZOHETERODIAZOLE COMPOUNDS | ENI SPA (IT) | 2018-12-12 | — | — | EP | disclosed |
| US-20170250300-A1 | LUMINESCENT SOLAR CONCENTRATOR COMPRISING DISUBSTITUTED BENZOHETERODIAZOLE COMPOUNDS | ENI S.P.A. (IT) | 2017-08-31 | — | — | US | disclosed |
| EP-3198658-A1 | LUMINESCENT SOLAR CONCENTRATOR COMPRISING DISUBSTITUTED BENZOHETERODIAZOLE COMPOUNDS | ENI S.p.A. (IT) | 2017-08-02 | — | — | EP | disclosed |
| US-9234225-B2 | Method for generating human milk oligosaccharides (HMOs) or precursors thereof | GLYCOM A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-20150183816-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | GLYCOM A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GLYCOM A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| EP-2864492-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | Glycom A/S (DK) | 2015-04-29 | — | — | EP | disclosed |
| EP-2864344-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | Glycom A/S (DK) | 2015-04-29 | — | — | EP | disclosed |
| US-20140234912-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2707493-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | Glycom A/S (DK) | 2014-03-19 | — | — | EP | disclosed |
| CN-103562401-A | Method for producing human milk oligosaccharides (HMOs) or precursors thereof | GLYCOM AS | 2014-02-05 | — | — | CN | disclosed |
| WO-2013190531-A1 | GLYCOSYLATED GALACTOSYL DISACCHARIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN CONSUMABLE PRODUCTS | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013190529-A1 | GLYCOSYLATED GALACTOSYL DISACCHARDDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN CONSUMABLE PRODUCTS | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013190530-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | GLYCOM A/S (DK) | 2013-12-27 | — | — | WO | disclosed |
| WO-2012156897-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250300-A1 | LUMINESCENT SOLAR CONCENTRATOR COMPRISING DISUBSTITUTED BENZOHETERODIAZOLE COMPOUNDS | SCO2, SCLY, SLC39A7 | TSHR 1085/4885ALDH1A1 2766/4885CA12 1455/4885 |
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GALE, SI, FUT6 | TSHR 1565/4885ALDH1A1 786/4885CA12 464/4885 |
| US-10312395-B2 | Luminescent solar concentrator comprising disubstituted benzoheterodiazole compounds | SCO2, SLC39A7, SCLY | TSHR 895/4885ALDH1A1 3009/4885CA12 1572/4885 |
| US-20150183816-A1 | MODIFIED GALACTOOLIGOSACCHARIDES | FUT6, GALE, FUT5 | TSHR 2455/4885ALDH1A1 1176/4885CA12 174/4885 |
| US-20140234912-A1 | METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | LCT, B4GALT1, GALNT1 | TSHR 1372/4885ALDH1A1 2229/4885CA12 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.